Synthesis, binding affinity, radiolabeling, and microPET evaluation of 4-(2-substituted-4-substituted)-8-(dialkylamino)-6-methyl-1-substituted-3,4-dihydropyrido[2,3-b]pyrazin-2(1H)-ones as ligands for brain corticotropin-releasing factor type-1 (CRF1) receptors
Graphical abstract
Section snippets
Acknowledgments
This research was sponsored by NIH/NIMH (2U19 MH069056). We acknowledge the use of shared instrumentation provided by Grants from the NIH and the NSF.
References and notes (34)
- et al.
Biol. Psychiatry
(1998) - et al.
Drug Discovery Today
(2010) - et al.
Methods
(2002) - et al.
Nucl. Med. Biol.
(2001) - et al.
Bioorg. Med. Chem.
(2006) - et al.
Nucl. Med. Biol.
(2014) - et al.
Bioorg. Med. Chem.
(2015) Mol. Imag. Biol.
(2003)Trends Pharmacol. Sci.
(2009)- et al.
J. Pharm. Sci.
(2012)
Neuropharmacology
Tetrahedron Lett.
Appl. Radiat. Isot.
Pharmacol. Rev.
J. Nucl. Med.
Science
Pharmacol. Rev.
Cited by (4)
The historical progression of positron emission tomography research in neuroendocrinology
2023, Frontiers in NeuroendocrinologyDifferential sensitivity of alcohol drinking and partner preference to a CRFR1 antagonist in prairie voles and mice
2020, Hormones and BehaviorCitation Excerpt :It is tempting to speculate that the lack of effects of CRFR1 antagonists on human alcohol use disorder is at least in part due to low levels of CRFR1 receptors in the human nucleus accumbens, similarly to prairie voles, and in contrast to mice and rats, species, in which the majority of preclinical work on CRFR1 antagonists has been performed. Unfortunately, a species-specific, in vivo CRFR1 radiotracer for primate PET/SPECT imagining studies to confirm sufficient receptor occupancy is currently unavailable (Lodge et al., 2014; Stehouwer et al., 2015a; Stehouwer et al., 2015b). In addition, density of CRFR1 within the human brain as compared to other species has yet to be established (Lodge et al., 2014).
Characterization of CRF<inf>1</inf> receptor antagonists with differential peripheral vs central actions in CRF challenge in rats
2017, PeptidesCitation Excerpt :In the PET studies in baboons, [11C]SN003 penetrated the BBB; however, regional variation in total binding could not be observed due to the rapid metabolism or the small number of CRF1 receptors [50]. Further efforts have been continuously made to identify reasonable PET ligands [52,53] and target occupancy of CRF1 receptor antagonists will enable us to predict active doses for clinical studies. So far, because ideal radiotracers for clinical use have not been obtained, effects of CRF1 receptor antagonist R317573 on regional cerebral glucose metabolism were studied using [18F]fluoro-2-deoxy-d-glucose (FDG) PET in healthy subjects [54].
Don’t stress about CRF: assessing the translational failures of CRF<inf>1</inf>antagonists
2017, Psychopharmacology